Opioids in Cardiovascular Disease: Therapeutic Options

被引:23
作者
Rawal, Hemangi [1 ]
Patel, Bhoomika M. [1 ]
机构
[1] Nirma Univ, Inst Pharm, Ahmadabad, Gujarat, India
关键词
opioid receptors; cardiovascular diseases; opioid agonist; opioid antagonist; PROTEIN-KINASE-C; NITRIC-OXIDE SYNTHASE; K-ATP CHANNEL; RECEPTOR STIMULATION; CONSCIOUS RABBITS; HEART-FAILURE; FREE-RADICALS; CEREBROVASCULAR DISEASES; INDUCED CARDIOPROTECTION; MYOCARDIAL-INFARCTION;
D O I
10.1177/1074248418757009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The World Health Organization suggests that the cardiovascular diseases (CVDs) are the major cause of mortality and account for two-thirds of the deaths all over the world. These diseases kill about 17 million people every year and 3 in every 10 deaths are due to these diseases. The past decade has seen considerable improvements in diagnosis as well as treatment of various heart diseases. Various new therapeutic targets are being identified through in-depth knowledge of the disease mechanisms which has favored the testing of new strategies leading to newer treatment options. Opioid peptides and G-protein-coupled opioid receptors (ORs) have been previously studied widely in terms of central nervous system actions in mitigating the pain and drug abuse. The OR agonism or antagonism induces cytoprotective states in the myocardium, rendering these receptors as an attractive target for protection of heart from the fatal heart diseases. The opioids can provide an extended window of protection of the heart from various diseases. Although the mechanisms may not be fully understood, they seem to play a crucial role in various CVDs such as hypertension, hyperlipidemia, ischemic heart disease myocardial ischemia, and congestive heart failure. Since these compounds are already being used in acute and chronic pain, soon these compounds might be approved for use as cardioprotective agents. The following review focuses on the new information acquired on the role of the ORs in various CVDs.
引用
收藏
页码:279 / 291
页数:13
相关论文
共 109 条
  • [21] Fryer RM, 2001, J PHARMACOL EXP THER, V296, P642
  • [22] Essential activation of PKC-δ in opioid-initiated cardioprotection
    Fryer, RM
    Wang, YG
    Hsu, AK
    Gross, GJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (03): : H1346 - H1353
  • [23] ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection
    Fryer, RM
    Hsu, AK
    Gross, GJ
    [J]. BASIC RESEARCH IN CARDIOLOGY, 2001, 96 (02) : 136 - 142
  • [24] Fryer RM, 1999, CIRC RES, V84, P846
  • [25] Fryer RM, 2000, J PHARMACOL EXP THER, V294, P451
  • [26] FRYER RM, 2004, AM J PHYSIOL-HEART C, V2, P1229
  • [27] CARDIOVASCULAR AND ENDOCRINE EFFECTS OF NALOXONE COMPARED IN NORMOTENSIVE AND HYPERTENSIVE PATIENTS
    FUENMAYOR, N
    CUBEDDU, L
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 126 (03) : 189 - 197
  • [28] GADDIS RR, 1982, J PHARMACOL EXP THER, V221, P282
  • [29] The mitochondrial K-ATP channel as a receptor for potassium channel openers
    Garlid, KD
    Paucek, P
    YarovYarovoy, V
    Sun, XC
    Schindler, PA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (15) : 8796 - 8799
  • [30] Global Health Observatory (GHO) data, 2016, GLOB HLTH OBS